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KSHV latency can be envisioned as an outcome that is balanced between factors that pro-
mote viral gene expression and lytic replication against those that facilitate gene silencing
and establish or maintain latency. A large body of work has focused on the activities of
the key viral regulatory proteins involved in KSHV latent or lytic states. Moreover, recent
studies have also begun to document the importance of epigenetic landscape evolution
of the KSHV viral genome during latency and reactivation. However, one area of KSHV
molecular virology that remains largely unanswered is the precise role of post-translational
modiﬁcations on the activities of viral factors that function during latency and reactivation.
Inthisreview,wewillsummarizethepost-translationalmodiﬁcationsassociatedwiththree
viral factors whose activities contribute to the viral state.The viral proteins discussed are
the two major KSHV encoded transcription factors, K-Rta (KSHV replication and transcrip-
tional activator) and K-bZIP (KSHV basic leucine zipper) and the viral latency-associated
nuclear antigen (LANA). A special emphasis will be placed on the role of the sumoylation
pathway in the modulation of the KSHV lifecycle. Newly uncovered small ubiquitin-like
modiﬁer (SUMO)-associated properties of LANA and K-Rta will also be presented, namely
LANA histone targeting SUMO E3 ligase activity and K-Rta SUMO-targeted ubiquitin ligase
function.
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INTRODUCTION
Reactivationfromalatentstateisanimportantfeatureofinfection
and disease caused by many herpesviruses. Although the molec-
ular mechanisms of reactivation have been extensively studied,
gaps exist in our current knowledge concerning the processes by
which these viruses establish, maintain, and emerge from latency.
KSHVlatencycanbeenvisionedastheoutcomebalancedbetween
factors that require viral gene expression and lytic replication
against those that are essential for establishment and/or main-
tenance of latent infection. In this review, we will provide an
update on three viral factors whose activities contribute to the
viral state with an emphasis on post-translational modiﬁcations
that modulate multiple functions of these factors. The viral pro-
teins discussed are the two major KSHV encoded transcription
factors,K-RtaandK-bZIPandthevirallatency-associatednuclear
antigen (LANA).
K-bZIP
K-bZIP (K8) is an early lytic gene and is among the earliest
viral genes expressed after acute infection or during reactivation
from latency. K-bZIP is a 237-amino acid protein containing a
basic and leucine zipper domain and is the structural and posi-
tional analog of Epstein–Barr virus (EBV) BZLF1 (Lin et al.,
1999). K-bZIP has been reported to be phosphorylated (Polson
et al., 2001), sumoylated (Chang et al., 2010; Lefort et al., 2010),
and acetylated (Lefort et al., 2010). K-bZIP directly associates
with K-Rta in KSHV infected cells and represses K-Rta-mediated
transactivation at a subset of KSHV promoters. This activity of
K-bZIP is subject to post-translational modulation via phos-
phorylation (Izumiya et al., 2007) and sumoylation (Izumiya
et al., 2005). As detailed below, K-bZIP repression activity on
K-Rta-mediated transactivation is regulated in an opposing man-
ner by these two post-translational modiﬁcations. While K-bZIP
repression is largely dependent on sumoylation, phosphoryla-
tion serves as a negative regulator. A schematic diagram of K-
bZIP and its post-translational modiﬁcation sites are presented in
Figure 1.
PHOSPHORYLATION
K-bZIP was reported to be phosphorylated on residues Thr 111
andSer167(Polsonetal.,2001;Izumiyaetal.,2007).Interestingly,
these sites are contained within cellular cyclin-dependent kinase
(CDK) recognition sites with the consensus sequence (S/T)PXR
suggesting that K-bZIP may be phosphorylated by CDKs. Indeed,
K-bZIP was conﬁrmed to be a substrate for several cellular CDK–
cyclincomplexesinvitro,includingCDK-2/cyclinA,CDK-1/cyclin
B, and CDK-2/cyclin E (Polson et al., 2001). K-bZIP was also
found to interact with, and be a substrate for, the viral protein
kinase (vPK, ORF36). vPK is a serine/threonine protein kinase
expressed from mRNAs with early and early-late kinetics and the
major vPK phosphorylation site on K-bZIP was determined to
also be residue threonine (T) 111 (Izumiya et al., 2007). K-bZIP
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FIGURE1|S c hematic representation of KSHV K-bZIP . K-bZIP protein
and its post-translational modiﬁcation sites as discussed in the text are
depicted. Phosphorylation (Phospho), acetylation (Ac), and sumoylation
(SUMO) sites are shown.The K-bZIP SUMO interaction motif (SIM) and
nuclear localization signal (NLS) are also indicated. Numbers indicate
amino acid position.
directly interacts with K-Rta and represses K-Rta activation of
certain K-Rta responsive promoters such as ORF57 and K-bZIP,
but not at other similarly responsive promoters such as PAN. The
functional signiﬁcance of K-bZIP T111 phosphorylation site with
respecttorepressionofK-Rta-mediatedtransactivationwasexam-
ined using a mutagenesis strategy in which T111 was changed
to a non-phospho acceptor reside alanine, or to aspartic acid, a
phospho-mimetic.Inco-transfectionexperimentswithK-Rtaand
a K-Rta responsive promoter construct,K-bZIP-T111D repressive
functionwassimilartowild-typeK-bZIP,whereasK-bZIP-T111A
was a more potent repressor. Moreover,K-bZIP-T111A was found
to be more heavily sumoylated than wild-type K-bZIP or K-bZIP-
T111D and overexpression of vPK reduced the sumoylation of
wild type K-bZIP. Taken together,these results are consistent with
a model whereby phosphorylation at T111 has a negative effect
on both the extent of sumoylation and the repressive activity of
K-bZIP (Izumiya et al., 2007). Thus K-bZIP activities are mod-
ulated by phosphorylation and sumoylation in an antagonistic
fashionsimilartoothercellulartranscriptionfactorssuchasELK-
1( Girdwood et al., 2003), AP-1 (Bossis et al., 2005), AIB1 (Wu
et al., 2006), progesterone receptor B (PR-B; Daniel et al., 2007;
Daniel and Lange,2009),STAT1 (Zimnik et al.,2009),and KAP-1
(Goodarzi et al., 2011). KSHV genome-wide reporter assays sup-
port the notion that K-bZIP preferentially represses early-lytic
genes but not late gene promoters (Ellison et al., 2009), consis-
tent with temporal regulation of viral gene expression,potentially
mediated, in part, through a K-bZIP SUMO-phospho switch.
ACETYLATION
K-bZIP was reported to be acetylated on multiple residues and
K145 was identiﬁed as one acetylation site (Lefort et al.,2010). K-
bZIP was previously found associated with CBP (Hwang et al.,
2001) and the ability of K-bZIP to repress transcription was
reported to be mediated through sequestration of CBP. In co-
transfection experiments, increasing amounts of CBP resulted in
increasedacetylationofK-bZIPandareversalofK-bZIP-mediated
repression of the IFNα-activated 2 ,5  -OAS gene. In addition to
effects on chromatin, CBP may be capable of acetylating K-bZIP.
However, the functional role of K-bZIP acetylation in the KSHV
life cycle remains to be seen.
SUMOYLATION
Sumoylation (small ubiquitin-like modiﬁer) was identiﬁed as
a reversible post-translational protein modiﬁcation in 1997
(reviewed in Geiss-Friedlander and Melchior, 2007). Three iso-
formsofSUMOexist:SUMO-1,-2,and-3.SUMO-2andSUMO-3
arehighlyhomologous(97%identityinthematureform),whereas
SUMO-1 is more distantly related to both (∼50%). Hundreds
of protein targets for SUMO-modiﬁcation have been identiﬁed,
and the majority of these are nuclear proteins. Similar to phos-
phorylation, sumoylation is a rapid and reversible modiﬁcation.
Moreover, in a manner similar to the binding of phosphorylated
tyrosineresiduesbysignalingmoleculescarryingphosphotyrosine
(PTB)orSrchomology2(SH2)domains,sumoylatedproteinsare
speciﬁcallyrecognizedbyproteinscontainingoneormoreSUMO-
interacting motifs (SIM). Analogous to ubiquitylation, conjuga-
tion of SUMO to target proteins is a multi-step process involving
an E1 activating enzyme heterodimer SAE1/SAE2 (AOS1/UBA2),
an E2 conjugating enzyme Ubc9 (ubiquitin-like protein SUMO-
1 conjugating enzyme 9), and an E3 ligase, which is believed
to provide speciﬁcity within the sumoylation pathway (Geiss-
FriedlanderandMelchior,2007).Sumoylationisahighlydynamic
process,anditsoutcomesareverydiverse,rangingfromchangesin
subcellular localization to altered activity and, in some cases, sta-
bilityof themodiﬁedprotein.Theunderlyingprincipleof sumoy-
lation is the alteration of inter- or intra-molecular interactions of
the modiﬁed substrate (Prudden et al.,2007;Uzunova et al.,2007;
Xieetal.,2007).ForDNAtumorviruses,theimmediate-earlyand
early gene products, which are transcriptional factors, are often
sumoylated. Examples include IE1 (immediate-early 1 protein)
and IE2 (immediate-early 2 protein) of cytomegalovirus (CMV;
Hofmannetal.,2000;Spengleretal.,2002;Hsuetal.,2004),E1and
E2 of human papillomavirus (HPV; Rosas-Acosta et al., 2005; Wu
etal.,2007),BZLF1of EBV(AdamsonandKenney,2001),K-bZIP,
and LANA2 of KSHV (Izumiya et al., 2005; Marcos-Villar et al.,
2009).Viral proteins are also known to modulate the sumoylation
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of speciﬁc cellular proteins. For example, HPV E7 protein and
adenovirus E1A protein block sumoylation of RB (Ledl et al.,
2005) and KSHV vPK inhibits the sumoylation of KAP-1 (Chang
et al., 2009). Viruses can also affect global sumoylation of cellu-
lar proteins by directly modulating the SUMO machinery. Avian
Adenovirus Gam1 is known to inhibit the SUMO E1 activating
enzyme by targeting the SAE1/SAE2 (AOS1/UBA2) heterodimer
tocullinRINGligases(CRLs)andpromotingSAE1ubiquitylation
and degradation (Colombo et al., 2002; Boggio et al.,2007).
The repressive activity of K-bZIP requires sumoylation at
lysine-158 and an intact leucine zipper region. Sumoylation at
this site is required for the association of K-bZIP with the cellular
E2SUMOconjugationenzymeUbc9.BothSUMO-1andSUMO-
2/3 were found conjugated to a signiﬁcant fraction (∼10%) of
endogenous K-bZIP in BCBL-1 cells. Mutation of lysine-158 to
arginine eliminated SUMO-modiﬁcation of K-bZIP in vivo with
a concomitant loss of the majority of K-bZIP repressive func-
tion. Although SUMO-modiﬁcation of K-bZIP may inﬂuence its
repressive function through several mechanisms,including effects
on the physical interaction between K-bZIP and K-Rta, it is likely
that a major effect of SUMO is mediated by its ability to recruit
Ubc9 to K-bZIP target promoters. Ubc9 binding to K-bZIP, as
well as co-occupancy of K-bZIP, K-Rta, and SUMO at target viral
promotershasbeenobserved.Basedontheseresults,wepredicted
thatK-bZIPmayfunctionasaSUMOE3ligaseorSUMOadaptor
which functions to deliver Ubc9 to potential substrates (Izumiya
etal.,2005).Inadditiontolysine-158,Lefortetal.(2010)havealso
identiﬁedapreviouslyunrecognizedsumoylationsiteinaK-bZIP
splice variant (K207).
Subsequently, Chang et al. (2010) have conﬁrmed that K-bZIP
functions as the prototypical viral SUMO E3 ligase. K-bZIP was
found to be a SIM-containing poly-SUMO-speciﬁc E3 ligase with
speciﬁcity for SUMO-2/3. As discussed above, K-bZIP had been
previously known to associate with Ubc9 (Izumiya et al., 2005),
Chang et al. further demonstrated that K-bZIP bound SUMO-2
and SUMO-3, but not SUMO-1. K-bZIP was found to contain a
SIM at amino acid residues 72 to 76, which was identical to that
of thecellularSUMO-ligases,PIAS1,andPIASx.Thesumoylation
activity of K-bZIP was dependent on an intact SIM, and K-bZIP
could catalyze its auto-sumoylation and the sumoylation of two
K-bZIP-interacting proteins,p53 and RB. In contrast,Lefort et al.
(2010) have reported that K-bZIP repression of interferon-α sig-
naling was SIM-independent but was dependent on K-bZIP K158
sumoylation site, a Ubc9 consensus binding site. As described
moredetailbelow,K-RtapreferentiallydegradesSUMO-modiﬁed
proteins, similar to an activity ascribed to HSV-1 ICP0 (Boutell
et al., 2011). This suggests that a balance between sumoylation
and SUMO-dependent degradation may be important for the
KSHV life cycle. As the assembly and disassembly of Promyelo-
cytic leukemia (PML; ND10) bodies at herpesvirus replication
complexesareSUMO-dependent,modulationof theSUMOenvi-
ronment by K-bZIP and K-Rta during lytic replication cycle may
helpdictatewhetherviralreplicationwillproceedorif latencywill
be established. Another potential role of K-bZIP may be to mark
proteins that are destined to be targeted by the SUMO-targeting
ubiquitin ligase (STUbL) activity of K-Rta (see below). Although
notfullyestablished,thisideaissupportedbythereportthatKSHV
LANA2 increases PML sumoylation, which facilitates its degrada-
tion by a cellular ubiquitin ligase (Marcos-Villar et al.,2009).
K-RTA
K-Rta is essential and sufﬁcient to induce lytic reactivation of the
latent KSHV genome in the BCBL-1 cell line model as well as
de novo infection model (Lukac et al.,1998,1999; Sun et al.,1998;
Nakamuraetal.,2003;Xuetal.,2005).K-Rtaisapotenttranscrip-
tionfactor,withanN-terminalputativeDNAbindingdomainand
a C-terminal transactivation domain (Lukac et al.,1999;West and
Wood, 2003). K-Rta possesses broad target sequence speciﬁcity,
and various K-Rta responsive promoter elements have been iden-
tiﬁed (Lukac et al., 1999; Chang et al., 2002; Deng et al., 2002;
Song et al.,2002;West and Wood,2003). K-Rta has been reported
to be phosphorylated (Lukac et al., 1999; Gwack et al., 2003),
poly(ADP-ribosyl)ated(Gwacketal.,2003),andubiquitylated(Yu
et al., 2005). A schematic diagram of K-Rta modiﬁcation sites is
presentedinFigure2,andtheconsequencesofthesemodiﬁcations
will be discussed.
FIGURE2|S c hematic representation of KSHV K-Rta. K-Rta
protein and its post-translational modiﬁcation sites as discussed in
the text are depicted. Phosphorylation (Phospho) site numbering
and PARylation (PAR) site localization of Gwack et al. (2003) is
utilized.The K-Rta nuclear localization signals (NLS-1 and NLS-2),
ring-ﬁnger like domain, SUMO interaction motifs (SIMs), and
serine/threonine (S/T) rich regions are also indicated. Numbers
indicate amino acid position.
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FIGURE 3 | SUMO-targeting ubiquitin ligase activity of KSHV K-Rta.
(A) 293T cells were co-transfected with his-tagged SUMO-2 and the indicated
K-Rta expression vector. Forty-eight hours later cellular lysates were prepared
and analyzed by immunoblotting using the indicated antibodies. (H145L,
ring-ﬁnger like domain mutant; ΔSIM, SIM deletion mutant). (B) In vitro
ubiquitin conjugation reactions were reconstituted using puriﬁed components
(E1, Ube1, 25 nM; E2, Ubc H5a, 50 nM; E3, K-Rta, 150 nM). Reaction
products were probed by immunoblotting. In the presence of K-Rta,
GST–SUMO was conjugated with ubiquitin. (C) KSHV promoter reporter assay.
293T cells were co-transfected with K-Rta wt or mutant and the indicated
KSHV promoter luciferase reporter. Forty eight hour later cellular lysates were
prepared and assayed for luciferase activity. Values represent the mean fold
induction (mean±SD, n=3 determinations) relative to the value derived from
reporter+empty vector set as=1 (K-Rta wt, blue; H145L, red; ΔSIM, yellow).
PHOSPHORYLATION
As part of an initial characterization of various aspects of ORF50
RNA and protein expression, structure, and function, K-Rta was
found to be highly phosphorylated in mammalian cells (Lukac
etal.,1999).Byimmunoblotanalysis,K-Rtaproteinmigratedwith
an apparent molecular mass of ∼110kDa, greater than the pre-
dicted value of 74kDa. Analysis of the K-Rta primary amino acid
sequence revealed several potential phosphorylation sites includ-
ing a C-terminal S/T-rich region, as well as additional consensus
phosphorylation sites for the cellular serine/threonine kinases
casein kinase-II and protein kinase C (PKC). Phosphatase treat-
mentof K-Rtaproteinpartiallyreducedtheslowerelectrophoretic
mobility of K-Rta suggesting that phosphorylation accounted for
most of the anomalous migration observed during SDS-PAGE
analysis of K-Rta. Subsequently, Gwack et al. (2003) identiﬁed
the Ste20-like kinase hKFC and poly(ADP-ribose) polymerase
1 (PARP-1, see below) as proteins that speciﬁcally interact with
the S/T-rich region of K-Rta. There are greater than 30 different
Ste20-related kinases in humans and three members of a novel
subfamily exhibit a high degree of homology to a Ste-like kinase
originally isolated from chick cells (Yustein et al., 2000, 2003).
hKFC is identical to JIK (Tassi et al., 1999), a kinase reported
to be negatively regulated by upstream tyrosine kinase receptors.
hKFC was shown to directly interact with K-Rta and phosphory-
late at serine (S505) and threonine (T506, T510, T515, and T516)
of K-Rta.Togetherwithpoly(ADP-ribosylation),phosphorylation
inactivates K-Rta transcriptional activity and was hypothesized to
serve as a contributor to the maintenance of KSHV latency. As
hKFC has been shown to localize to the cytoplasm (Yustein et al.,
2003), whereas K-Rta is primarily nuclear (Lukac et al., 1998),
the interaction and phosphorylation by hKFC was proposed to
potentially affect K-Rta localization.
POLYADP-RIBOSYLATION (PARYLATION)
AlthoughthehistoricalfocusofPARP-1hasbeenitsroleinthecel-
lular DNA damage response,studies have also revealed important
roles for PARP-1 in transcriptional regulation. Poly-ADP-ribose
(PAR) is a large negatively charged polymer that functions in
both its free form or in the context of protein post-translational
modiﬁcations. In mammalian cells, the majority of PAR pro-
duction is catalyzed by PARP-1 and targets of PARP-1 catalytic
activity include histones, transcription factors, nuclear enzymes,
andnuclearstructuralcomponents(seeKrishnakumarandKraus,
2010;forarecentreview).SimilartohKFCdescribedabove,PARP-
1 was identiﬁed by mass spectrometry as a protein that interacted
withtheS/T-richregionofK-Rta(Gwacketal.,2003).Theinterac-
tionwasmappedtotheNAD+ bindingdomainofPARP-1andthis
interaction mediated the PARylation of K-Rta. Synergistic effects
between PARP-1 and hKFC on K-Rta binding and its subsequent
modiﬁcation were observed. The in vitro interaction between
K-Rta and PARP-1 was increased by the addition of hKFC and
conversely, in vitro interaction between K-Rta and hKFC was also
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increased with the addition of PARP-1. The reciprocal increases
in binding were accompanied by enhanced phosphorylation and
PARylationofK-RtabyhKFCandPARP-1,respectively.Moreover,
PARP-1 and hKFC were found to act as repressors of K-Rta activ-
ity in reporter assays and in the efﬁciency of K-Rta-mediated viral
reactivation. A combination of K-Rta mutational analysis, ChIP
assays, and reporter activity measurements in PARP-1 knockout
cellssuggestedamodelinwhichPARP-1andhKFC,actingascellu-
lar sensors of herpesvirus infection,interfere directly or indirectly
with the recruitment of K-Rta onto target promoters, leading to
a decrease in K-Rta-mediated transcriptional activation (Gwack
et al.,2003).
SUMOYLATION
Herpesvirus infections are controlled by acquired and innate
defenses involving cellular, humoral, and cytokine-mediated
responses. In recent years, a concept of intrinsic antiviral resis-
tance has emerged as an additional antiviral defense mechanism
that operates within individual cells. Unlike cytokine-mediated
responses,intrinsicantiviralresistanceinvolvestheactionsof pre-
existing cellular proteins that, in the case of herpesviruses, act to
repress viral transcription. PML nuclear bodies (ND10 or PML–
NBs) have been identiﬁed as an important factor of intrinsic
antiviralresistanceagainstherpesvirus.ComponentsofPML–NBs
are recruited to sites associated with the viral chromosome soon
after genomes enter the nucleus. Both SUMO-modiﬁcation and
SIMs of PML are required for formation of PML–NBs as well
as recruitment to the viral genome. Viral gene expression is
silenced by PML–NBs through deacetylation of local histones,
whichinhibitsviralreplication.Importantly,herpesvirusinfection
often disrupts PML–NBs, resulting in antagonism of both innate
and intrinsic immune responses in early infection (Everett et al.,
2006, 2008; Lukashchuk et al., 2006; Tavalai et al., 2006; Boutell
et al.,2011).
Promyelocytic leukemia–NBs are mobile organelles that form
distinct sub-compartments in the cell nucleus as described in a
number of reviews (Bernardi and Pandolﬁ, 2007; Borden, 2008;
Nagai et al., 2011). Assembly of PML–NBs, “storage” sites for
SUMO, depends on the sumoylation of PML and other com-
ponents such as Daxx, SP-100, and ATRX (Ishov et al., 1999;
Zhong et al., 2000; Seeler et al., 2001; Fu et al., 2005). In addition,
chromatin can be an integral part of PML–NBs. For example, a
particular class of PML–NBs exists in tumor cells that maintain
their telomeres in the absence of telomerase activity by a process
referred to as alternative lengthening of telomeres (ALT). Recent
studies identiﬁed that ALT is caused by the genomic mutations
in Daxx or ATRX, both of which are localized in PML–NBs in a
SUMO-andSIM-dependentmanner(Linetal.,2006;Berubeetal.,
2008; Heaphy et al., 2011). Interestingly, an ATRX–Daxx complex
was recently identiﬁed as a histone chaperone, which speciﬁcally
deposits the histone H3 variant, H3.3 (Drane et al., 2010; Gold-
berg et al., 2010; Lewis et al., 2010), leading to a possibility that
PML–NBs function as a center of epigenetic gene regulation.
Like HSV-1 ICP0, our recent studies identiﬁed that K-Rta
contained multiple SIMs and bound to SUMO in vitro.I n
co-transfection experiments with SUMO-2, K-Rta was found to
markedly decrease the level of total cellular SUMO-2 modiﬁed
proteins and mutations in the K-Rta SIM or ring-ﬁnger like
domain signiﬁcantly impaired this activity (Figure 3A). Using
puriﬁed components, K-Rta was shown to conjugate ubiquitin
to SUMO and SUMO-chains (Figure 3B). In addition, K-Rta
preferentiallytargetsSUMO-modiﬁedproteinsforubiquitylation;
thusK-RtaisabletofunctionasaSTUbLwhichiscapableof ubiq-
uitylation of SUMO and SUMO conjugates in vitro and in vivo
(Figures 3A,B; Izumiya et al., unpublished). The prototypical
STUbL, cellular RNF4, was ﬁrst identiﬁed as a ubiquitin ligase
that functions to maintain genomic stability, and was recently
reported to be a ubiquitin ligase targeting SUMO-containing pro-
teins, including sumoylated PML (Sun et al., 2007; Tatham et al.,
2008).Membersofthisubiquitinligasefamilyincludemammalian
RNF4 and the heterodimers Hex3–Slx8 and Rfp1–Slx8 in S. cere-
visiae and S. pombe, respectively (Uzunova et al., 2007; Xie et al.,
2007).SimilartoHSV-1ICP0andcellularRNF4,KSHVK-Rtadis-
rupts the PML body in ubiquitin ligase dependent fashion (data
not shown). Sumoylation is often linked to gene repression due
to its ability to serve as a platform to recruit strong co-repressors
such as SETDB1, HDAC1, and HDAC2 via SUMO-SIM interac-
tions. Accordingly, K-Rta’s ability to remove SUMO is relevant
to its transactivation functions. Mutations in SIM or ring-ﬁnger
like domain signiﬁcantly impaired K-Rta transactivation activity.
We observed that the K-bZIP promoter, a well recognized pro-
moter transactivated by K-Rta, is activated by wild-type K-Rta,
but not by H145L (ring-ﬁnger) mutant or a K-Rta SIM mutant
(Figure 3C). Interestingly, the K12 (Figure 3C) or PAN promoter
(not shown) were relatively unaffected. Thus,it is likely that there
areSUMO-dependentandSUMO-independentpromoters,which
may depend on local chromatin structure and mode of K-Rta
recruitment. These results suggest that K-Rta,in addition to being
a strong transactivator, has an ability to regulate the local SUMO
environment; the latter may contribute to its former functions
through disassembly of SIM-containing co-repressors.
UBIQUITYLATION
K-Rta was found to contain an E3 ubiquitin ligase activity which
was associated with the regulation of the cellular levels of inter-
feron regulatory factor 7 (IRF7; Yu et al., 2005). During the char-
acterization of this activity,it was determined that that K-Rta was
subjected to self-ubiquitylation. Three residues were identiﬁed in
the Cys/His-rich region of K-Rta which was found to be critical
for both K-Rta auto-ubiquitylation and for degradation of IRF7.
These residues, Cys131, Cys141, and His145 were proposed to be
part of a novel Cys-rich domain extending from K-Rta amino
acids 118–207 (C3HC3). However, this ring-ﬁnger like domain
shows no signiﬁcant homology with any previously described
sequences conserved among E3 ligases. Based on analogy to other
transcriptional activators,the K-Rta auto-ubiquitylation function
may serve as a “degron” to activate gene expression (Muratani
and Tansey, 2003; Kodadek et al., 2006). Indeed, K-Rta mutants
that harbor a mutation in ring-ﬁnger like domain are more sta-
ble than K-Rta Wt. This stability is associated with a concomitant
loss of transactivation function (Figure 3C). Further studies are
required to dissect the contribution of K-Rta auto-ubiquitylation
and repressor degradation activity to K-Rta transactivation (Yang
et al.,2008).
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LANA
KSHV (LANA/ORF73) is key regulatory protein that is essential
for the establishment and maintenance of viral latency. LANA is a
DNAbindingproteinthatisafunctionalhomologofEBVEBNA1.
LANA binds to the viral latent origin of replication, located at
the terminal repeat (TR) sequence of the KSHV genome, and is
highly expressed in all KSHV-associated disorders (Kedes et al.,
1997; Schulz, 2001; Hu et al., 2002; Komatsu et al., 2004; Verma
et al., 2007; Kelley-Clarke et al., 2009; Ganem, 2010; Mesri et al.,
2010). LANA functions as both a transcriptional activator and
a repressor depending on the context of promoters and cell line
interrogated (An et al., 2005; Kelley-Clarke et al., 2009). Accord-
ingly, LANA has been shown to associate with a broad range of
transcriptional regulators such as RBP-Jκ, CBP, Daxx, BRD2, RB,
p53,and Sp-1 (Friborg et al.,1999; Platt et al.,1999; Radkov et al.,
2000;Limetal.,2001;Vermaetal.,2004;Lanetal.,2005;Murakami
et al.,2006). LANA function is regulated and/or mediated by pro-
tein partner interaction. In addition, LANA activity is regulated
by post-translational modiﬁcations, including phosphorylation
(Plattetal.,1999;Fujimuroetal.,2005;Bajajetal.,2006;Varjosalo
et al., 2008; Cheng et al., 2009; Cha et al., 2010), acetylation (Lu
et al., 2006), PARylation (Ohsaki et al., 2004), sumoylation (Izu-
miya et al., unpublished), and arginine methylation (Campbell
et al.,2011). These modiﬁcation sites are depicted in Figure 4.
PHOSPHORYLATION
Latency-associatednuclearantigeninteractswithandisphospho-
rylated by several kinases including glycogen synthase kinase 3
(GSK-3; Fujimuro and Hayward, 2003; Fujimuro et al., 2005; Liu
et al., 2007), Pim-1 and Pim-3 (Bajaj et al., 2006; Varjosalo et al.,
2008; Cheng et al., 2009), and DNA-PK/Ku (Cha et al., 2010).
LANA is also phosphorylated by an unidentiﬁed kinase medi-
ated through an interaction of LANA with RING3 (Platt et al.,
1999).Instudiesdesignedtocharacterizetheinteractionof LANA
with RING3, Platt et al. (1999) ﬁrst described phosphorylation
of LANA in vitro. The interaction between RING3 and LANA
resultedinserine/threoninephosphorylationofLANAonresidues
located between LANA amino acids 951 and 1107,and binding of
RING3 to LANA facilitated the phosphorylation of LANA via an
unknown co-immunoprecipitating kinase. However, the identity
of the kinase and its role in the KSHV life cycle remains to be
determined.
Using yeast two-hybrid screening with LANA as the bait pro-
tein, GSK-3 was shown to interact with LANA and through co-
immunoprecipitation LANA interacted with both GSK-3α and
GSK-3β in transfected cells. This interaction resulted in increased
nuclear accumulation of GSK-3β (Fujimuro and Hayward,2003).
Fujimuro et al. (2005) further showed that GSK-3β phosphory-
lated multiple N-terminal residues of LANA in vitro and in KSHV
infected PEL cells. Phosphorylation of LANA by GSK-3β was nec-
essary for the LANA/GSK-3β interaction. GSK-3β predominantly
phosphorylatespre-phosphorylated(primed)substratesthatcon-
tain the motif S/TxxxS/Tp, where the +4 position S or T residue
has prior phosphorylation mediated by another priming kinase
(reviewed in Forde and Dale, 2007). LANA was found to require
priming phosphorylation in vitro in order to serve as a GSK-3β
substrate; mitogen-activated protein kinase (MAPK) and casein
kinase-I (CK-I) could function as priming kinases, while CK-II
could not. Subsequently ERK1/2 was also found to phosphorylate
and prime LANA for subsequent GSK-3β phosphorylation (Liu
et al., 2007). A GSK-3β priming pocket mutant (R96A) could not
bindtoLANA.Interestingly,inco-transfectionexperiments,GSK-
3β present in a LANA–GSK-3β complex was unable to phospho-
rylate a primed peptide substrate. These results were interpreted
to suggest that GSK-3β phosphorylation sites on LANA function
to increase the afﬁnity of LANA binding to GSK-3β and simul-
taneously provide a competitive substrate that minimizes poten-
tial phosphorylation events on other non-complexed substrates
(Fujimuro et al., 2005). Taken together, these results suggested a
model in which LANA sequesters GSK-3β in the nucleus leading
to dysregulation of the kinase function in both the cytoplasmic
(β-catenin stability) and nuclear (gene reprogramming) com-
partments (Fujimuro and Hayward, 2003; Fujimuro et al., 2005;
Liu et al., 2007). Aspects of this model have been challenged
by a report, in which LANA overexpression showed no effect
on endogenous β-catenin levels (Hagen, 2009); this report
FIGURE4|S c hematic representation of KSHV LANA. LANA protein and
its post-translational modiﬁcation sites as discussed in the text are depicted.
Phosphorylation (Phospho) sites and the arginine methylation (Me) site are
shown.The N-terminal histone binding domain, nuclear localization signal
(NLS) and SUMO interaction motif (SIM) are also indicated. Numbers indicate
amino acid position.
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demonstrates the complexity of the interaction and its context
dependence.
Bajaj et al. (2006) identiﬁed LANA as a substrate for Pim-1
kinase. The Pim-1 gene was ﬁrst identiﬁed as a common provi-
ral insertion site of the Moloney murine leukemia virus (proviral
insertionsiteMuLV;Cuypersetal.,1984).Pim-1encodesaSer/Thr
kinase, which belongs to the group of calcium/calmodulin-
regulated kinases. This gene is expressed primarily in B-lymphoid
and myeloid cell lines, and is overexpressed in hematopoietic
malignancies. Pim-1 plays a role in signal transduction in blood
cells, contributing to cell growth and survival, and thus may
provide a selective advantage in tumorigenesis (Bachmann and
Moroy, 2005). Pim-1 was shown to bind to the C-terminus of
LANA and to phosphorylate LANA at its N-terminus, speciﬁcally
serine residues 205 and 206. Using human kinome expression
screening, Varjosalo et al. (2008) conﬁrmed that Pim-1 could
phosphorylate LANA and augment viral reactivation primed
by low levels of K-Rta. Cheng et al. (2009) further showed
that another Pim family kinase member, namely Pim-3, could
also phosphorylate LANA at serines 205 and 206. Moreover,
ectopic expression of Pim-1 or Pim-3 in rKSHV.219-infected
Vero cells enhanced the level of reactivation when co-expressed
with low levels of exogenous K-Rta. Mechanistically, Pim-1
and Pim-3 phosphorylation of LANA was shown to antagonize
LANA-dependent transcriptional repression of a synthetic TR
reporter as well as decrease the ability of LANA to inhibit K-
Rta auto-activation of its own promoter. As Pim-1 and Pim-3
are up-regulated during viral reactivation (Cheng et al., 2009)a
model was proposed in which these kinases participate in reac-
tivation by negative modulation of LANA function via direct
phosphorylation.
Latency-associated nuclear antigen-dependent latent episomal
replicationisalsoregulatedbyphosphorylation.TheDNA-PK/Ku
complex bound and phosphorylated LANA (Cha et al., 2010).
Uninfected B cell extracts were fractionated over a GST afﬁn-
ity resin containing LANA amino acids 1–52. Among the pro-
teins found to interact with this LANA fragment were DNA-
dependent protein kinase (DNA-PK) catalytic subunit (DNA-
PKcs), Ku70, and Ku86. In agreement with Ohsaki et al., 2004;
see below), Cha et al. also identiﬁed PARP-1 as a LANA interact-
ing protein. The phosphorylation of LANA by the DNA-PK/Ku
complex was wortmannin-sensitive and mapping data suggested
that LANA was phosphorylated at multiple positions. Inter-
estingly, transient replication of a TR-containing plasmid was
reduced when a phosphorylation-competent N-terminal LANA
fragment was fused to a C-terminal LANA fragment that sup-
portedTR-dependentreplication.Twosimilarlydesignedmutants
that were not phosphorylated by DNA-PK/Ku were not defective
in this assay. Overexpression of Ku70 also impaired transient TR-
dependentreplicationinco-transfectionassaysconductedin293T
cells. Although overexpression of Ku86 did not affect transient
replicationassayssetupin293Tcells,theauthorsnotedanincrease
in TR-dependent replication when the assays were conducted in
Ku86 heterozygous HCT116 Ku86+/− cells when compared to
a HCT116 Ku86+/+ background. Taken together, these results
suggest that the DNA-PK/Ku complex negatively regulates latent
episomal replication.
ACETYLATION
Latency-associatednuclearantigenwasreportedtobelysineacety-
lated in response to sodium butyrate or trichostatin A-mediated
reactivation(Luetal.,2006).Althoughthesite(s)of lysineacetyla-
tion on LANA were not mapped, LANA acetylation was observed
in the presence of HDAC inhibition using either ectopic LANA
expression or endogenous LANA in BCBL-1 cells as substrate.
LANA acetylation was observed in HDAC inhibitor-treated cells
using immunological detection with antibodies speciﬁc for acetyl
lysine or by metabolic labeling of cells with [14C]-sodium acetate
followedbyﬂuorography.LANAacetylationoccurredduringreac-
tivation and this was accompanied by disruption of the inter-
action between LANA and the cellular proteins Sp-1 and his-
tone H2B. ChIP analysis of HDAC inhibitor-treated BCBL-1 cells
also revealed a loss of LANA from the K-Rta promoter region
that occurred within the same time frame as LANA acetylation.
Together, these results suggest that LANA acetylation contributes
to the ORF50 transcriptional de-repression during the early stage
of KSHV lytic cycle reactivation.
PARYLATION
As mentioned previously, PARP has been historically studied in
the context of the DNA damage response, but PARP-1 has more
recently been linked to the regulation of transcription and chro-
matin structure. PARP-1 binds to a variety of DNA structures,
nucleosomes, and chromatin-associated proteins (Krishnakumar
and Kraus, 2010). Ohsaki et al. (2004) reported that LANA was
a target of PARP-1 and was poly(ADP-ribosyl)ated. Using a TR
afﬁnity column and BC3 cell extracts, PARP-1 was isolated as a
TR interacting protein. TR binding by PARP-1 was independent
of LANA and was also observed with BJAB cell extracts; how-
ever the afﬁnity column elution proﬁles of PARP-1 and LANA
were similar. In addition, PARP-1 was found to co-localize with
LANA in the nucleus, suggesting that LANA may be a poten-
tial PARP-1 substrate. A small fraction of LANA present in BC3
anti-LANAimmunoprecipitateswasfoundtoreactwithanti-PAR
antibody. Moreover, when LANA immunoprecipitates were incu-
bated with puriﬁed human PARP-1 and NAD in vitro, a species
consistent with NAD-incorporated LANA was observed. Intrigu-
ingly, PARP-1 activity appeared to control viral copy number in
infected cells. When BC3 cells were treated with hydroxyurea,
a compound that elevates PARP activity, a ∼4-fold decrease in
KSHV copy number was observed over the course of a 5-day
treatment period. Conversely, when cells were similarly treated
with compounds that decreased PARP activity (niacinamide and
3-aminobenzamide), KSHV copy numbers increased ∼8-fold.
Interestingly, for hydroxyurea-treated cells, the decrease in viral
copy number was accompanied by an increase in the PARylation
signal detected in LANA immunoprecipitates. Although mecha-
nistic details remain to be elucidated, these results suggest that
the viral replication and/or episome partitioning functions of
LANA may be inﬂuenced by cellular PARylation activity. Similar
results were reported for EBV EBNA1, which was found inter-
act with both PARP-1 (Deng et al., 2002; Tempera et al., 2010)
and telomere-associated PARPs,Tankyrases-1 and -2 (Deng et al.,
2002,2005).BothPARP-1andTankyrase-1werefoundtocatalyze
PARylation of EBNA1 and negatively regulate EBNA1 origin of
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FIGURE 5 | Latency-associated nuclear antigen enhances histone
sumoylation in vitro and in vivo. (A) LANA enhances histone H2A and
H2B SUMO-modiﬁcation in vitro.Thein vitro SUMO conjugation reaction
was performed with puriﬁed histone octamer (5μg; Roche) as a substrate.
SAE1/2 (E1, 50nM), Ubc9 (E2, 50nM), and HA-SUMO-2 (50μM) were
incubated in reaction buffer containing 1mM ATP and MgCl2 with or without
a catalytic amount of LANA (50nM). In the presence of LANA, H2A, and
H2B SUMO-modiﬁcation is enhanced.The arrows indicate SUMO-modiﬁed
histones, which were increased in SUMO-reaction mixtures supplemented
with LANA (three lanes from left). Full-length LANA Wt and mutant proteins
were prepared with recombinant baculoviruses (B) and used as an E3
SUMO-ligase for in vitro SUMO conjugation reactions. CBB, Coomassie
brilliant blue. (C) Histone binding domain and SUMO-interacting motif of
LANA are necessary for its SUMO-ligase function. LANA Wt but neither a
histone binding mutant (HB Mut) or SUMO-binding mutant (SIM Mut) can
catalyze SUMO-modiﬁcation of histones.The corresponding number of
SUMO-chains is indicated on the right (20kDa increments). LANA ring-ﬁnger
like domain is dispensable for LANA-mediated SUMO conjugation of
histones (Ring Mut). (D) Correlation between LANA recruitment sites and
SUMO-enriched loci on the latent KSHV genome. ChIP analyses were
performed with anti-LANA or anti-SUMO-2 antibodies using latent BCBL -1
cells. ChIP with LANA antibody was hybridized with custom-made KSHV
tiling arrays and SUMO-ChIP was directly analyzed by sequencing
(ChIP-seq). Enrichment over input DNA is shown (upper panel). Counts and
position of sequence reads of SUMO-ChIP are shown in the bottom panel.
SUMO-2 is enriched where LANA is recruited. Annotation of the KSHV
genome is shown in the middle panel.The KSHV terminal repeat region is
located at the extreme right of the annotated genome. (E) cDNA microarray
analyses. RNA was prepared from indicated LANA stable cells or vector
control stable cells and hybridized to Affymetrix human whole genome U133
plus 2.0 arrays. Raw data was subjected to baseline transformation and
analyzed by hierarchical clustering using GeneSpring GX11 software. Genes
highly repressed by LANA wt but not mutants are indicated by blue vertical
lines to the right.
plasmid replication (OriP) activity in a PAR-dependent manner.
Althoughtheeffectsof thecellularDNAdamageresponseonviral
replication and gene expression are multi-faceted and enigmatic
(Lilley et al., 2007; Weitzman et al., 2010) these result suggest that
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current PARP-1 inhibitors (see Rouleau et al., 2010; for a recent
review) under evaluation for treatment of certain malignancies
might be worth examining for their efﬁcacy as a treatment for
KSHV infected individuals.
ARGININE METHYLATION
Our lab has determined that LANA is a substrate for protein argi-
nine methyltransferase (PRMT)-1 in vitro and in vivo, and the
major methylation site was mapped to the N-terminus of LANA
(Arg 20; Campbell et al., 2011). Although, there was no effect
of methylation on LANA nuclear localization or nuclear matrix
association, methylation at this position did affect the interaction
of LANA with histone octamers in vitro and with KSHV chro-
matin in vivo. In vitro,the histone octamer-LANA interaction was
strengthenedwhentheR20sitewasreplacedwithamethyl-mimic
residue,phenylalanine(R20F).Similarly,usingLANAChIPanaly-
sis,consistentlyhigheramountsofKSHVDNAcouldberecovered
from cells harboring latent KSHV bacmids containing the LANA
R20F mutant. These results suggest that arginine methylation at
positionR20maypotentiallyinﬂuenceasub-populationof LANA
protein within infected cells resulting in increased interaction of
LANA with KSHV-associated chromatin.
SUMOYLATION
Sumoylation-modiﬁcation plays important roles in assembling
protein complexes to regulate gene expression. Recent studies
support a model in which the SUMO-modiﬁcation has a signif-
icant impact on heterochromatin formation by recruiting SIM-
containing co-repressors (Uchimura et al., 2006; Stielow et al.,
FIGURE 6 | KSHV SUMO-dependent balance.The outcome of the KSHV
life cycle is depicted as a balance between the functions of the viral factors
LANA, K-Rta, and K-bZIP which are mediated through their
SUMO-dependent activities.The SUMO E3 ligase activities of K-bZIP and
LANA and the STUbL activity of K-Rta are shown (see text for details).
2008). Accordingly, our lab has found that LANA is both heav-
ily sumoylated and binds SUMO. By creating a SUMO-rich
environment on local chromatin, we propose LANA may be able
to condense chromatin, which leads to gene silencing mediated
through its SIM domain. Interestingly, when we searched the
LANA protein sequence for the SUMO-modiﬁcation consensus
motif (V/I/L-K-x-E), which is a well-established Ubc9 recogni-
tionsequence,therewasnosuchmotif.Thisobservationindicates
that LANA itself may bind SUMO to recruit Ubc9. Since LANA
is heavily modiﬁed by SUMO in the absence of an E3 SUMO-
ligase in vitro, LANA is likely to bind to the SUMO–Ubc9 com-
plex (“active-SUMO”) directly for its own SUMO-modiﬁcation.
Further detailed SUMO-binding analyses with a panel of GST–
LANA deletion proteins conﬁrmed that LANA possesses a SIM
domain at its C-terminus. These result prompted us to investigate
if LANAfunctionsasanE3SUMO-ligase,becausetherecruitment
of SUMO–Ubc9 complex (active-SUMO) is one of the mecha-
nisms for catalyzing the conjugation of SUMO. Although LANA
associates with multiple proteins, we decided to focus on chro-
matin components and histone modifying enzymes involved in
epigenetic gene regulation. We chose to use histone octamers as
substrates, because LANA has been shown to associate with his-
tones at the H2A–H2B acidic patch (Barbera et al., 2006). In
addition,SUMO-modiﬁcationofhistones,especiallyhistoneH2B,
is linked to chromatin condensation (Nathan et al., 2006). Our
results conﬁrmed that LANA can enhance SUMO-modiﬁcation
of histones in vitro (Figure 5A). The puriﬁed proteins that were
used in the in vitro SUMO-reactions are shown in Figure 5B.
SumoylationreactionsusingtwoLANAmutantsclearlyshowthat
both a histone binding mutation and SIM mutation signiﬁcantly
diminishedhistonetargetingSUMO-ligaseactivity,supportingthe
idea that LANA needs to bind both substrate and SUMO for the
activity (Figure 5C). Our results demonstrate for the ﬁrst time
that a viral protein acts as an E3 SUMO-ligase to increase SUMO-
modiﬁcation of histones, and which is likely to be involved in the
formationof localizedSUMO-richchromatin.Next,weexamined
the distribution of SUMO and LANA across the latent KSHV epi-
some. Comparison of the SUMO-ChIP assay with KSHV tiling
array data indicated that the overlap of local SUMO occupancy
with LANA binding sites within the KSHV genome was exten-
sive (Figure 5D). Together, these experiments show that LANA
can increase the content of histone SUMO-modiﬁcation in vitro
(isolated system without other proteins), and in vivo at the local
chromatin level. Based on these data, we propose that LANA
increases local SUMO-modiﬁcation, and thus impacts and initi-
atesepigeneticchangesatthesesites.Theseepigeneticchangesmay
causally associate with the observed silencing of both the KSHV
genome and at speciﬁc genomic loci of the host cell. We therefore
examinedwhetherassemblyofaSUMO-mediatedcomplexwould
translate into gene repression. If LANA SUMO-ligase function is
important for such a complex formation,the LANA SUMO-ligase
mutants [SUMO-binding mutant (ΔSIM) and histone binding
mutant (HBM)] should have impaired gene repression func-
tion. To answer this question, cDNA microarray analyses were
employed to probe the signiﬁcance of histone targeting SUMO-
ligase function in gene regulation. LANA wild-type and ΔSIM
and HBM mutant stable SLK cells were generated. These cells
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lines expressed equivalent amounts of LANA or mutant LANA
proteins when examined by western blotting with anti-Flag anti-
body. As shown in Figure 5E, both ΔSIM and HBM mutants had
signiﬁcantlyimpairedgenerepressionactivityrelativetowild-type
LANA cells; these two cell lines showed gene expression patterns
very similar to vector control SLK cells. Taken together, these
results demonstrate that LANA recruits SUMO–Ubc9 complexes
through SUMO-binding, and facilitates local histone SUMO-
modiﬁcation. Importantly, enrichment of SUMO at LANA bind-
ing sites may also prepare the KSHV genome for reactivation by
generating a suitable target for K-Rta. Obviously, further studies
are required to test this possibility. A putative SUMO-mediated
KSHV latency-reactivation model is depicted in Figure 6.
SUMMARY
Althoughtherearenumerousstudiesdescribingpost-translational
modiﬁcationsof severalKSHVregulatoryfactors,thereappearsto
be a fundamental gap in our knowledge as to precisely how,where
and when these modiﬁcations affect the regulatory functions
associated with each protein. These are very difﬁcult questions to
address for several reasons. The modiﬁcations affect only a small
percentage of the total pool of a particular molecule,are transient
in nature,and,in many cases,detection is technically demanding.
Nevertheless,thisareaof herpesvirusresearchshouldbefruitfulin
yielding novel insights into both virus-host interactions and basic
cellularsignalingpathways.Therecentadvancementof proteomic
approaches will certainly help to answer these questions.
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